Alfimeprase (Amgen)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAlfimeprase (Amgen)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionFibrinogen stimulants
TargetsFibrinogen
Therapy Area/IndicationsIschemic StrokeArterial Occlusive Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArca Biopharma IncBayer AG
Active IndicationsN/A
Inactive IndicationsIschemic StrokeArterial Occlusive Diseases

Other Information

ATC CodeN/A
Related LinksN/A